Soluble guanylate cyclase redox state under hypoxia or hypoxia/reoxygenation in isolated monkey coronary arteries

J Pharmacol Sci. 2014;125(2):169-75. doi: 10.1254/jphs.14046fp. Epub 2014 May 23.

Abstract

Hypoxia or hypoxia/reoxygenation impairs nitric oxide (NO)-mediated relaxation through the increase in superoxide generation in monkey coronary arteries. Soluble guanylate cyclase (sGC), the target enzyme of NO, has been shown to change from the NO-sensitive reduced form to the NO-insensitive oxidized/heme-free form under substantial oxidative stress, so the present study investigated whether hypoxia or hypoxia/reoxygenation influences sGC redox equilibrium. In isolated monkey coronary arteries without endothelium, the relaxation caused by the sGC stimulator BAY 41-2272 (Emax: 93.3% ± 2.2%) was somewhat impaired under hypoxia (Emax: 86.3% ± 2.6%) or hypoxia/reoxygenation (Emax: 86.1% ± 3.2%), whereas that by the sGC activator BAY 60-2770 (Emax: 86.0% ± 3.2%) was significantly augmented under hypoxia (Emax: 94.4% ± 1.3%) or hypoxia/reoxygenation (Emax: 95.5% ± 1.1%). In addition, cGMP formation in response to BAY 41-2272 and BAY 60-2770 was inhibited and stimulated, respectively, under hypoxia or hypoxia/reoxygenation. The effects of hypoxia or hypoxia/reoxygenation on BAY 41-2272- and BAY 60-2770-induced vasorelaxation were completely canceled by the treatment with the superoxide dismutase mimetic tempol. These findings suggest that sGC redox equilibrium in the coronary artery is shifted towards the NO-insensitive form under hypoxia or hypoxia/reoxygenation and that superoxide seems to play an important role in this shift.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzoates / antagonists & inhibitors
  • Benzoates / pharmacology
  • Biphenyl Compounds / antagonists & inhibitors
  • Biphenyl Compounds / pharmacology
  • Coronary Vessels / enzymology*
  • Coronary Vessels / metabolism
  • Coronary Vessels / physiopathology*
  • Cyclic GMP / metabolism
  • Female
  • Guanylate Cyclase / metabolism*
  • Hydrocarbons, Fluorinated / antagonists & inhibitors
  • Hydrocarbons, Fluorinated / pharmacology
  • Hypoxia / enzymology*
  • Hypoxia / metabolism
  • Hypoxia / physiopathology*
  • In Vitro Techniques
  • Macaca
  • Male
  • Nitric Oxide / metabolism
  • Nitric Oxide / physiology
  • Oxidation-Reduction
  • Oxidative Stress
  • Pyrazoles / antagonists & inhibitors
  • Pyrazoles / pharmacology
  • Pyridines / antagonists & inhibitors
  • Pyridines / pharmacology
  • Solubility
  • Superoxide Dismutase / pharmacology
  • Superoxides / metabolism*
  • Vasodilation* / drug effects

Substances

  • 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine
  • 4-(((4-carboxybutyl) (2- (5-fluoro-2-((4'-(trifluoromethyl) biphenyl-4-yl)methoxy)phenyl)ethyl) amino)methyl)benzoic acid
  • Benzoates
  • Biphenyl Compounds
  • Hydrocarbons, Fluorinated
  • Pyrazoles
  • Pyridines
  • Superoxides
  • Nitric Oxide
  • Superoxide Dismutase
  • Guanylate Cyclase
  • Cyclic GMP